These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26979830)

  • 1. A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia.
    Connor KM; Mahoney E; Jackson S; Hutzelmann J; Zhao X; Jia N; Snyder E; Snavely D; Michelson D; Roth T; Herring WJ
    Int J Neuropsychopharmacol; 2016 Aug; 19(8):. PubMed ID: 26979830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder.
    Connor KM; Ceesay P; Hutzelmann J; Snavely D; Krystal AD; Trivedi MH; Thase M; Lines C; Herring WJ; Michelson D
    Int J Neuropsychopharmacol; 2017 Aug; 20(8):613-618. PubMed ID: 28582570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.
    De Boer P; Drevets WC; Rofael H; van der Ark P; Kent JM; Kezic I; Parapatics S; Dorffner G; van Gerven J; Beneš H; Keicher C; Jahn H; Seiden DJ; Luthringer R
    J Psychopharmacol; 2018 Jun; 32(6):668-677. PubMed ID: 29848147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
    Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
    Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Ivgy-May N; Snyder E; Liu K; Snavely DB; Krystal AD; Walsh JK; Benca RM; Rosenberg R; Sangal RB; Budd K; Hutzelmann J; Leibensperger H; Froman S; Lines C; Roth T; Michelson D
    Biol Psychiatry; 2016 Jan; 79(2):136-48. PubMed ID: 25526970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials.
    Gotfried MH; Auerbach SH; Dang-Vu TT; Mishima K; Kumar D; Moline M; Malhotra M
    Drugs Aging; 2024 Sep; 41(9):741-752. PubMed ID: 39120786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis.
    Chabi A; Zhang Y; Jackson S; Cady R; Lines C; Herring WJ; Connor KM; Michelson D
    Cephalalgia; 2015 Apr; 35(5):379-88. PubMed ID: 25106663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Orexin Receptor Antagonist, Almorexant, in Elderly Patients With Primary Insomnia: A Randomized, Controlled Study.
    Roth T; Black J; Cluydts R; Charef P; Cavallaro M; Kramer F; Zammit G; Walsh J
    Sleep; 2017 Feb; 40(2):. PubMed ID: 28364509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
    Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M
    JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia.
    Brooks S; Jacobs GE; de Boer P; Kent JM; Van Nueten L; van Amerongen G; Zuiker R; Kezic I; Luthringer R; van der Ark P; van Gerven JM; Drevets W
    J Psychopharmacol; 2019 Feb; 33(2):202-209. PubMed ID: 30644312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orexin Receptor Antagonism in Painful Diabetic Neuropathy: A Phase 2 Trial With Filorexant.
    Joseph Herring W; Ge JY; Jackson S; Assaid C; Connor KM; Michelson D
    Clin J Pain; 2018 Jan; 34(1):37-43. PubMed ID: 28448426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference.
    Black J; Pillar G; Hedner J; Polo O; Berkani O; Mangialaio S; Hmissi A; Zammit G; Hajak G
    Sleep Med; 2017 Aug; 36():86-94. PubMed ID: 28735928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.
    Murphy P; Moline M; Mayleben D; Rosenberg R; Zammit G; Pinner K; Dhadda S; Hong Q; Giorgi L; Satlin A
    J Clin Sleep Med; 2017 Nov; 13(11):1289-1299. PubMed ID: 29065953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.
    Fietze I; Bassetti CLA; Mayleben DW; Pain S; Seboek Kinter D; McCall WV
    Drugs Aging; 2022 Oct; 39(10):795-810. PubMed ID: 36098936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study.
    Uchiyama M; Kambe D; Imadera Y; Kajiyama Y; Ogo H; Uchimura N
    Psychopharmacology (Berl); 2022 Jul; 239(7):2143-2154. PubMed ID: 35296912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep?
    Drake CL; Kalmbach DA; Cheng P; Roth T; Tran KM; Cuamatzi-Castelan A; Atkinson R; Singh M; Tonnu CV; Fellman-Couture C
    J Clin Sleep Med; 2019 Sep; 15(9):1285-1291. PubMed ID: 31538599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder.
    Dauvilliers Y; Zammit G; Fietze I; Mayleben D; Seboek Kinter D; Pain S; Hedner J
    Ann Neurol; 2020 Mar; 87(3):347-356. PubMed ID: 31953863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder.
    Chepke C; Jain R; Rosenberg R; Moline M; Yardley J; Pinner K; Kumar D; Perdomo C; Filippov G; Atkins N; Malhotra M
    Postgrad Med; 2022 Apr; 134(3):316-325. PubMed ID: 35254948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study.
    Scharf M; Rogowski R; Hull S; Cohn M; Mayleben D; Feldman N; Ereshefsky L; Lankford A; Roth T
    J Clin Psychiatry; 2008 Oct; 69(10):1557-64. PubMed ID: 19192438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory Safety of Lemborexant in Healthy Subjects: A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Crossover Study.
    Cheng JY; Moline M; Zammit GK; Filippov G; Bsharat M; Hall N
    Clin Drug Investig; 2021 May; 41(5):449-457. PubMed ID: 33723806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.